Holen Sie sich die Stockscreener-App
195.09
0.48%
-0.94
Handel nachbörslich:
195.09
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Axsome Therapeutics Is Maintained at Equal-Weight by Morgan Stanley - Moomoo
AXSM Maintains Rating by Morgan Stanley -- Price Target Lowered to $247 - GuruFocus
H.C. Wainwright reiterates Axsome stock Buy rating at $290 target By Investing.com - Investing.com Canada
AXSOME THERAPEUTICS, INC. : TRUIST SECURITIES ASSUMES COVERAGE WITH BUY RATING; TARGET PRICE $285 VS $200 - webull.com
$100 Invested In Axsome Therapeutics 10 Years Ago Would Be Worth This Much Today - Benzinga
AXSM Stock Price and Chart — NASDAQ:AXSM - TradingView
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Truist Securities maintains Buy rating on Axsome Therapeutics, $285 price target - TradingView
Truist Raises Price Target on Axsome Therapeutics to $285 From $200, Keeps Buy Rating - marketscreener.com
Truist initiates Axsome stock coverage with buy rating on growth By Investing.com - Investing.com Nigeria
Truist initiates Axsome stock coverage with buy rating on growth - Investing.com
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day - The Manila Times
Axsome Therapeutics Announces Results of the Shared Goals - GlobeNewswire
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Promising 37% Upside Potential Amidst Strong Buy Ratings - DirectorsTalk Interviews
Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction - MarketBeat
Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues - Yahoo Finance
Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story? - Yahoo Finance
Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference - MarketBeat
Bank of America Corp DE Acquires Shares of 452,491 Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics (AXSM) Reported New Clinical Data In Depression And Alzheimer’s Agitation - Yahoo Finance
Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy? - Yahoo Finance
Axsome Therapeutics (NASDAQ:AXSM) Receives "Overweight" Rating from Piper Sandler - MarketBeat
Axsome Therapeutics Price Target Maintained With a $258.00/Share by Piper Sandler - Moomoo
Piper Sandler reiterates Overweight rating on Axsome Therapeutics, $258 price target - TradingView
Is Axsome Therapeutics a Buy on the Dip? - Yahoo Finance
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026 - The Manila Times
Axsome Therapeutics Presents Ten Posters Exemplifying its - GlobeNewswire
Baird Financial Group Inc. Acquires New Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics at H.C. Wainwright conference: growth broadens By Investing.com - Investing.com South Africa
Axsome Therapeutics at H.C. Wainwright conference: growth broadens - Investing.com
Engineers Gate Manager LP Has $2.74 Million Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. $AXSM Shares Purchased by California State Teachers Retirement System - MarketBeat
Axsome Therapeutics at Morgan Stanley conference: growth, pipeline and cash - Investing.com
Axsome Therapeutics, Inc. (AXSM) Investor Outlook: A Biotech Stock with 29% Upside and Robust Growth Potential - DirectorsTalk Interviews
About Axsome Therapeutics, Inc. rStock - Coinbase
Axsome Therapeutics Inc (19X) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2036 – DelveInsight | Eli Lilly, Teva Pharma, Axsome Therapeutics, AEON Biopharma, Charleston Lab, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’ - Stocktwits
Axsome Therapeutics (NASDAQ:AXSM) Trading Up 7%Should You Buy? - MarketBeat
Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Axsome Therapeutics (AXSM) and Ocugen (OCGN) - The Globe and Mail
Axsome at cantor healthcare conference: auvelity growth accelerates By Investing.com - Investing.com South Africa
Transcript : Axsome Therapeutics, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02 - marketscreener.com
AXSM: AUVELITY's commercial expansion and deep pipeline position the company for strong near-term growth - TradingView
Axsome at cantor healthcare conference: auvelity growth accelerates - investing.com
AXSM: AUVELITY's rapid growth and robust CNS pipeline position the company for significant expansion - TradingView
Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Axsome Therapeutics Inc (19X) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc (19X) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics at Wells Fargo conference: growth broadens By Investing.com - Investing.com South Africa
Axsome Therapeutics Inc (19X) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc (19X) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Axsome reports strong growth for its CNS drugs ... - Pluang
Axsome Therapeutics Inc (19X) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc (19X) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
AXSM: AUVELITY's growth accelerates with new indications and strong pipeline progress, supported by solid financials - TradingView
Transcript : Axsome Therapeutics, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 03 - marketscreener.com
Axsome Therapeutics at Wells Fargo conference: growth broadens - investing.com
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):